Although aGITR administered as a monotherapy or as a dual therapy reduced Tregs (Figure 4), we did not observe improved tumor suppression or synergy when CD4 depletion was combined with Vax/aGITR/aPD-1 therapy. The gene discussed is CD4; the disease is neoplasm.